Ono, Medarex research PD-1 cancer antibody
Japanese pharmaceutical company Ono and Medarex (antibodies for oncology, autoimmune disorders, inflammation, and infectious diseases) have partnered to research and develop a fully human antibody against the PD-1 receptor as a potential treatment for cancer.
- Includes Royalty or Profit Split Information
- Product or Technology Swap
- R&D and Marketing (Licensing)
- Trial Collaborations
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com